Genomic Solutions: Aktuelle gute Nachrichten!*! - 500 Beiträge pro Seite

[notation]

Frisch aus der Druckerei:

Genomic Solutions, Inc. hat sich mit PerkinElmer schnell und gütlich geeinigt.
Beide Seiten sind mit dem Ergebnis sehr zufrieden. Die Zusammenarbeit wird bestärkt. PerkinElmer verzichtet auf sein Recht, die Aktien von GNSL innerhalb von 2 Jahren komplett übernehmen zu können (callable common stock). Jetzt ist der Weg frei für viele institutionelle Anleger in GNSL investieren zu können, da es sich jetzt um "ganz normale handelbare Aktien" (common stock) handelt.
Die Tatsache, daß der Rechtsstreit dermaßen schnell und gentlemanlike beigelegt wurde und die Tatsache, daß die GNSL Aktien nun wesentlich attraktiver sind für die Großen, dürfte der Aktie einen guten Schub geben.
In der nächsten Woche wird es dazu noch eine Pressekonferenz geben.

Das nenne ich noch eine gute Nachricht so früh am Morgen!!!

Zitat der Veröffentlichung von GNSL und PKI:

Genomic Solutions Inc. (ticker: GNSL, exchange: NASDAQ) News Release -
19-Apr-2001

Genomic Solutions and PerkinElmer Lawsuit Settlement Includes
Termination of Call Option

ANN ARBOR, Mich.--(BW HealthWire)--April 19, 2001--Genomic
Solutions Inc. (Nasdaq:GNSL), a leading global supplier of automated
solutions for genomic and proteomic research, announced that
Genomic Solutions and PerkinElmer Inc. (NYSE:PKI) have agreed to
end the litigation between the two companies that had been pending
in Delaware Chancery Court.

PerkinElmer had sought declaratory relief to prevent Genomic
Solutions from entering into a transaction with a third party that, had
the transaction been completed, would have eliminated PerkinElmer`s
call right on Genomic Solutions callable common stock.

The parties have entered into an agreement that ends all litigation
and settles all disputes between them. As part of the settlement,
Genomic Solutions has purchased 873,016 shares, or about 69
percent of the total shares of Genomic Solutions common stock held
by PerkinElmer, at PerkinElmer`s original purchase price.

As a result, PerkinElmer`s right to acquire Genomic Solutions callable
common stock automatically terminates, and all outstanding callable
common shares of Genomic Solutions automatically convert into
shares of common stock.

"PerkinElmer is an important strategic partner for Genomic Solutions,
and we are pleased to end this litigation in a manner that is
constructive for both parties," said Jeffrey S. Williams, president and
chief executive officer of Genomic Solutions. "It became increasingly
clear to us after our IPO last year that eliminating the call option on
our company was a strategic necessity.

"We believe we are now in an improved position to implement our
business plan, and we are glad that certain institutional and other
investors who are restricted from purchasing callable common stock,
a nontraditional security, will no longer be prohibited from investing in
our company. Also, with PerkinElmer retaining approximately 1.6
percent of Genomic Solutions common stock, its objectives are
directly aligned with the objectives of all our shareholders," Williams
continued.

According to Patrik O. Dahlen, president of PerkinElmer Life Sciences:
"We are glad to resolve this situation in such a positive manner.
Owing to the enhanced distribution relationship between the two
companies, Genomic Solutions has become an increasingly important
partner for PerkinElmer. We are pleased to have settled the litigation
in a way that really strengthens our business relationship."

Pursuant to Genomic Solutions` certificate of incorporation,
PerkinElmer had the right to cause Genomic Solutions to redeem its
callable common stock for a period of two years beginning on Oct. 23,
2000. As the sole shareholder of Genomic Solutions common stock, if
PerkinElmer had caused Genomic Solutions to redeem its callable
common stock, PerkinElmer would have been the sole shareholder of
Genomic Solutions.

A more complete description of PerkinElmer`s call right is described in
Genomic Solutions` filings with the Securities and Exchange
Commission referenced below. As set forth in Genomic Solutions`
Certificate of Incorporation, PerkinElmer`s call right terminates in the
event that PerkinElmer sells more than 50 percent of the shares of
Genomic Solutions common stock held by PerkinElmer at the time
Genomic Solutions completed its initial public offering.

As PerkinElmer has sold approximately 69 percent of its shares of
Genomic Solutions common stock, PerkinElmer`s call right has
terminated. As a result, each share of Genomic Solutions callable
common stock automatically converts into one share of common
stock.
Zitatende

Nachdem wir in den letzten Tagen schon einen mächtigen Anstieg des Aktienkurses gesehen haben, möchte ich mal sagen:
"Das war erst der Anfang, das beste kommt noch!!"

[notation]

Heute an der Nasdaq plus 12 %, d.h. morgen sind die GNSL wohl
hier nicht mehr unter 4 Euro zu haben.